Suppr超能文献

澳大利亚角质形成细胞癌发病率:基于人群的发病率趋势回顾和终生风险估计。

Keratinocyte cancer incidence in Australia: a review of population-based incidence trends and estimates of lifetime risk.

机构信息

Department of Population Health, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia; Faculty of Medicine, University of Queensland, Brisbane, Australia;

Department of Population Health, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia; Faculty of Medicine, University of Queensland, Brisbane, Australia.

出版信息

Public Health Res Pract. 2022 Mar 10;32(1):3212203. doi: 10.17061/phrp3212203.

Abstract

OBJECTIVES

To review the most recent population-based estimates of keratinocyte cancer incidence in Australia, to describe the trends over time and to calculate lifetime risk of developing these skin cancers.

METHODS

We conducted a literature search of PubMed/MEDLINE from 2001 to August 2021 to identify relevant literature. We defined eligible articles as those reporting population-based studies of adults and excluded studies that reported only on high-risk or paediatric populations, or on incidence of precursor or related lesions. We summarised identified studies qualitatively. We calculated lifetime risk of developing keratinocyte cancer using the methods of Cancer Research UK, adjusting for multiple primaries and the competing risk of death.

RESULTS

We identified six eligible studies. In the absence of compulsory notifications of keratinocyte cancer to state and territory cancer registries in Australia, all estimates of national incidence rates of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) have limitations. The most recent population-based estimates of people annually affected for the period 2011-2014 (BCC: 770/100 000 person years; SCC: 271/100 000 person years) represent the lower end of the possible range of incidence rates nationally. Because many people are affected by multiple lesions, the lesion-based incidence estimates are more than double the person-based rates (BCC: 1565/100 000 person years; SCC: 580/100 000 person years). Analyses of temporal trends in treatment rates (excisions, cryotherapy/curettage) show increases over time, most marked for people aged 55 years or older. We estimate that 69% of Australians will have at least one excision for histologically confirmed keratinocyte cancer in their lifetime (60% to age 79 years).

CONCLUSION

The available evidence on national incidence rates is out of date and of moderate quality, but indicates very high rates of keratinocyte cancer in Australia. We recommend that population-based cancer registries work towards statutory notification and routine reporting of keratinocyte cancer in Australia.

摘要

目的

综述澳大利亚基于人群的角化细胞癌发病率的最新数据,描述其随时间的变化趋势,并计算罹患这些皮肤癌的终生风险。

方法

我们对 2001 年至 2021 年 8 月期间的 PubMed/MEDLINE 数据库进行了文献检索,以确定相关文献。我们将符合条件的文献定义为报告成年人的基于人群研究的文献,并排除仅报告高危人群或儿科人群、或报告癌前病变或相关病变发病率的文献。我们对已识别文献进行了定性总结。我们使用英国癌症研究中心的方法计算了罹患角化细胞癌的终生风险,对多重原发性疾病和死亡的竞争风险进行了调整。

结果

我们共确定了 6 项符合条件的研究。由于澳大利亚各州和地区癌症登记处没有强制性报告角化细胞癌,因此所有关于基底细胞癌(BCC)和鳞状细胞癌(SCC)的国家发病率估计都存在局限性。最近基于人群的 2011-2014 年期间每年发病人数估计(BCC:770/100000 人年;SCC:271/100000 人年)代表了全国发病率的可能范围的下限。由于许多人受到多种病变的影响,基于病变的发病率估计是基于人数的发病率的两倍多(BCC:1565/100000 人年;SCC:580/100000 人年)。对治疗率(切除术、冷冻疗法/刮除术)的时间趋势分析显示,随着时间的推移呈上升趋势,55 岁及以上人群的上升幅度最为明显。我们估计,69%的澳大利亚人在一生中至少会有一次因组织学证实的角化细胞癌而接受切除术(60 岁至 79 岁)。

结论

现有的关于国家发病率的证据已经过时,且质量中等,但表明澳大利亚的角化细胞癌发病率非常高。我们建议基于人群的癌症登记处努力实现澳大利亚角化细胞癌的法定通知和常规报告。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验